HLA-DR4 antigen and lymph node metastases in poorly differentiated adenocarcinoma of the stomach

Ogoshi, Kyouji; Tajima, Tomoo; Mitomi, Toshio; Tsuji, Kimiyoshi

doi:10.1002/1097-0142(19940501)73:9<2250::aid-cncr2820730903>3.0.co;2-l

Cited by 10 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, we found correlations between specific patterns of HLA antigens and metastasis and secondary cancer, in addition to the response to therapies after gastrectomies [6][7][8][9] . However, it remains difficult to predict the response to therapy during the decision making process about treatment.…”

Section: Introductionmentioning

confidence: 89%

HLA-B54 is a candidate of response to Fluoropyrimidine plus PSK therapy in gastric cancer

Ogoshi

Isono

2009

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

It is not well known that the correlation between HLA antigens and response to cancer therapy. To evaluate the correlation among patients' outcome, HLA antigens and therapies, we used the hierarchical clustering analysis (Ward method). We examined HLA antigens as biomarkers as well as models of gene polymorphism in 1753 gastric cancer patients followed over 25 years after treatment. Among these patients, we identified that HLA haplotypes; HLA-B54-Cw1-DQ4-DR4, might be restricting to Fluoropyrimidine drugs plus PSK therapy in gastric cancer. HLA haplotypes including HLA-B54 were candidate predictors for response to FPSK therapy in gastric cancer. HLAs will be useful biomarkers for response to therapy in Japanese patients.

show abstract

Section: Introductionmentioning

confidence: 89%

HLA-B54 is a candidate of response to Fluoropyrimidine plus PSK therapy in gastric cancer

Ogoshi

Isono

2009

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

“…We previously reported that Japanese cancer patients could be classified into four groups, Type 1, 2, 3, and 4, according to the incidence of HLA antigens, by using quantification method III [11][12][13] . In that study, we retrospectively examined HLA antigens in gastric cancer patients before surgery and evaluated the surgical outcomes according to the HLA classification by quantification method III.…”

Section: Introductionmentioning

confidence: 99%

Outcome of HLA-oriented therapy for gastric cancer in retrospective and prospective study.

Ogoshi

Koyanagi

Tsuji

et al. 2008

Ann. Cancer Res. Therap.

Self Cite

View full text Add to dashboard Cite

There are no strategies to predict a patient's response to therapy. In a previous report, we classified Japanese patients into four groups according to the incidence of HLA antigens, by using the quantification method III. We examined the HLA antigens of patients before surgery and evaluated their outcome according to the HLA classification by this quantification method. We also reported that HLA-oriented therapy was better than old fashioned therapy. The aim of the present study was to evaluate whether HLA classification is useful in the treatment of individual cancer patients, by using a consecutive retrospective study series of 1932 patients from Jan 1977 to May 1996 and a consecutive prospective study series of 582 patients from Jun 1996 to Aug 2005, all of whom received gastrectomies. There were significant differences between male patients who agreed to get the recommended therapy (the patients in agreement) and those who did not (the patients in disagreement), those with lymph node metastasis, those with undifferentiated adenocarcinoma, and those in stage 3A. Moreover, stage 2 and 3A patients benefitted from HLA-oriented therapy in a prospective study. In conclusion, our results showed that it is beneficial to examine HLA antigens preoperatively, that HLA-oriented therapy is promising, and that we must determine predictive factors for response to therapy in the future. We concluded that HLA antigens are promising predictive markers for cancer treatment.

show abstract

Vogt‐Koyanagi‐Harada disease‐like uveitis induced by nivolumab in metastatic renal cell carcinoma

Imai,

Koguchi,

Harigane

et al. 2024

IJU Case Reports

View full text Add to dashboard Cite

IntroductionNivolumab can cause various immune‐related adverse events; it rarely induces Vogt‐Koyanagi‐Harada‐disease‐like uveitis. Vogt‐Koyanagi‐Harada‐disease is reported to be closely associated with human leukocyte antigen‐DR4.Case presentationA 68‐year‐old man with metastatic renal cancer underwent nephrectomy. Computed tomography showed multiple lung tumors, raising suspicion of lung metastases. However, one lung hilar mass was suspected to be primary lung cancer, leading to a lobectomy, which subsequently revealed lung metastases of renal cancer. The patient underwent nivolumab treatment but developed Vogt‐Koyanagi‐Harada‐disease‐like uveitis as an immune‐related adverse event. Human leukocyte antigen‐DR4 alleles were identified, and the uveitis improved with topical steroids. He maintained partial response of lung metastases after nivolumab resumption. Immunohistochemical staining revealed significantly higher human leukocyte antigen‐DR4 expression in lung metastasis than primary renal cancer.ConclusionDespite inducing Vogt‐Koyanagi‐Harada‐disease‐like uveitis, nivolumab controlled cancer progression effectively. Immunohistochemical staining results suggest the potential involvement of human leukocyte antigen‐DR4 expression in both the onset of Vogt‐Koyanagi‐Harada‐disease‐like uveitis and nivolumab efficacy.

show abstract

HLA-DR4 antigen and lymph node metastases in poorly differentiated adenocarcinoma of the stomach

Cited by 10 publications

References 8 publications

HLA-B54 is a candidate of response to Fluoropyrimidine plus PSK therapy in gastric cancer

HLA-B54 is a candidate of response to Fluoropyrimidine plus PSK therapy in gastric cancer

Outcome of HLA-oriented therapy for gastric cancer in retrospective and prospective study.

Vogt‐Koyanagi‐Harada disease‐like uveitis induced by nivolumab in metastatic renal cell carcinoma

Contact Info

Product

Resources

About